Literature DB >> 27380512

Cost analysis of whole genome sequencing in German clinical practice.

Marika Plöthner1, Martin Frank2, J-Matthias Graf von der Schulenburg2.   

Abstract

OBJECTIVES: Whole genome sequencing (WGS) is an emerging tool in clinical diagnostics. However, little has been said about its procedure costs, owing to a dearth of related cost studies. This study helps fill this research gap by analyzing the execution costs of WGS within the setting of German clinical practice.
METHODOLOGY: First, to estimate costs, a sequencing process related to clinical practice was undertaken. Once relevant resources were identified, a quantification and monetary evaluation was conducted using data and information from expert interviews with clinical geneticists, and personnel at private enterprises and hospitals. This study focuses on identifying the costs associated with the standard sequencing process, and the procedure costs for a single WGS were analyzed on the basis of two sequencing platforms-namely, HiSeq 2500 and HiSeq Xten, both by Illumina, Inc. In addition, sensitivity analyses were performed to assess the influence of various uses of sequencing platforms and various coverage values on a fixed-cost degression.
RESULTS: In the base case scenario-which features 80 % utilization and 30-times coverage-the cost of a single WGS analysis with the HiSeq 2500 was estimated at €3858.06. The cost of sequencing materials was estimated at €2848.08; related personnel costs of €396.94 and acquisition/maintenance costs (€607.39) were also found. In comparison, the cost of sequencing that uses the latest technology (i.e., HiSeq Xten) was approximately 63 % cheaper, at €1411.20.
CONCLUSIONS: The estimated costs of WGS currently exceed the prediction of a 'US$1000 per genome', by more than a factor of 3.8. In particular, the material costs in themselves exceed this predicted cost.

Entities:  

Keywords:  Cost analysis; German clinical practice; Whole genome sequencing

Mesh:

Year:  2016        PMID: 27380512     DOI: 10.1007/s10198-016-0815-0

Source DB:  PubMed          Journal:  Eur J Health Econ        ISSN: 1618-7598


  36 in total

Review 1.  The complexities of predictive genetic testing.

Authors:  J P Evans; C Skrzynia; W Burke
Journal:  BMJ       Date:  2001-04-28

Review 2.  Mapping complex disease loci in whole-genome association studies.

Authors:  Christopher S Carlson; Michael A Eberle; Leonid Kruglyak; Deborah A Nickerson
Journal:  Nature       Date:  2004-05-27       Impact factor: 49.962

3.  Accurate prediction of genetic values for complex traits by whole-genome resequencing.

Authors:  Theo Meuwissen; Mike Goddard
Journal:  Genetics       Date:  2010-03-22       Impact factor: 4.562

Review 4.  Keeping up with the next generation: massively parallel sequencing in clinical diagnostics.

Authors:  John R ten Bosch; Wayne W Grody
Journal:  J Mol Diagn       Date:  2008-10-02       Impact factor: 5.568

5.  Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium.

Authors:  D Ford; D F Easton; M Stratton; S Narod; D Goldgar; P Devilee; D T Bishop; B Weber; G Lenoir; J Chang-Claude; H Sobol; M D Teare; J Struewing; A Arason; S Scherneck; J Peto; T R Rebbeck; P Tonin; S Neuhausen; R Barkardottir; J Eyfjord; H Lynch; B A Ponder; S A Gayther; M Zelada-Hedman
Journal:  Am J Hum Genet       Date:  1998-03       Impact factor: 11.025

6.  American Society of Clinical Oncology policy statement update: genetic testing for cancer susceptibility.

Authors: 
Journal:  J Clin Oncol       Date:  2003-04-11       Impact factor: 44.544

Review 7.  Next-generation sequencing for research and diagnostics in kidney disease.

Authors:  Kirsten Y Renkema; Marijn F Stokman; Rachel H Giles; Nine V A M Knoers
Journal:  Nat Rev Nephrol       Date:  2014-06-10       Impact factor: 28.314

8.  A tale of three next generation sequencing platforms: comparison of Ion Torrent, Pacific Biosciences and Illumina MiSeq sequencers.

Authors:  Michael A Quail; Miriam Smith; Paul Coupland; Thomas D Otto; Simon R Harris; Thomas R Connor; Anna Bertoni; Harold P Swerdlow; Yong Gu
Journal:  BMC Genomics       Date:  2012-07-24       Impact factor: 3.969

Review 9.  Sequencing pools of individuals - mining genome-wide polymorphism data without big funding.

Authors:  Christian Schlötterer; Raymond Tobler; Robert Kofler; Viola Nolte
Journal:  Nat Rev Genet       Date:  2014-09-23       Impact factor: 53.242

10.  A guide for the design of evolve and resequencing studies.

Authors:  Robert Kofler; Christian Schlötterer
Journal:  Mol Biol Evol       Date:  2013-11-09       Impact factor: 16.240

View more
  7 in total

1.  Whole exome sequencing in molecular diagnostics of cancer decreases over time: evidence from a cost analysis in the French setting.

Authors:  I Borget; J Bonastre; Arnaud Bayle; N Droin; B Besse; Z Zou; Y Boursin; S Rissel; E Solary; L Lacroix; E Rouleau
Journal:  Eur J Health Econ       Date:  2021-03-25

2.  Cost of cancer diagnosis using next-generation sequencing targeted gene panels in routine practice: a nationwide French study.

Authors:  Patricia Marino; Rajae Touzani; Lionel Perrier; Etienne Rouleau; Dede Sika Kossi; Zou Zhaomin; Nathanaël Charrier; Nicolas Goardon; Claude Preudhomme; Isabelle Durand-Zaleski; Isabelle Borget; Sandrine Baffert
Journal:  Eur J Hum Genet       Date:  2018-01-24       Impact factor: 4.246

3.  The cost and cost trajectory of whole-genome analysis guiding treatment of patients with advanced cancers.

Authors:  Deirdre Weymann; Janessa Laskin; Robyn Roscoe; Kasmintan A Schrader; Stephen Chia; Stephen Yip; Winson Y Cheung; Karen A Gelmon; Aly Karsan; Daniel J Renouf; Marco Marra; Dean A Regier
Journal:  Mol Genet Genomic Med       Date:  2017-03-12       Impact factor: 2.183

4.  Estimating the costs of genomic sequencing in cancer control.

Authors:  Louisa G Gordon; Nicole M White; Thomas M Elliott; Katia Nones; Anthony G Beckhouse; Astrid J Rodriguez-Acevedo; Penelope M Webb; Xing J Lee; Nicholas Graves; Deborah J Schofield
Journal:  BMC Health Serv Res       Date:  2020-06-03       Impact factor: 2.655

5.  Positioning whole exome sequencing in the diagnostic pathway for rare disease to optimise utility: a protocol for an observational cohort study and an economic evaluation.

Authors:  Robin Z Hayeems; Francois Bernier; Kym M Boycott; Taila Hartley; Christine Michaels-Igbokwe; Deborah A Marshall
Journal:  BMJ Open       Date:  2022-10-10       Impact factor: 3.006

6.  Continuing the sequence? Towards an economic evaluation of whole genome sequencing for the diagnosis of rare diseases in Scotland.

Authors:  Michael Abbott; Lynda McKenzie; Blanca Viridiana Guizar Moran; Sebastian Heidenreich; Rodolfo Hernández; Lynne Hocking-Mennie; Caroline Clark; Joana Gomes; Anne Lampe; David Baty; Ruth McGowan; Zosia Miedzybrodzka; Mandy Ryan
Journal:  J Community Genet       Date:  2021-08-20

Review 7.  Value-based genomics.

Authors:  Jun Gong; Kathy Pan; Marwan Fakih; Sumanta Pal; Ravi Salgia
Journal:  Oncotarget       Date:  2018-01-30
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.